Search

The inevitable feedback between the environmental and energy crisis within the next decades can probably trigger and/or promote a global imbalance in both financial and public health terms. To handle this difficult situation, in the last decades, many different classes of materials have been recruited to assist in the management, production, and storage of so-called clean energy. Probably, ferromagnets, superconductors and ferroelectric/piezoelectric materials stand at the frontline of applications that relate to clean energy. For instance, ferromagnets are usually employed in wind turbines, superconductors are commonly used in storage facilities and ferroelectric/piezoelectric materials are employed for the harvesting of stray energy from the ambient environment. In this work, we focus on the wide family of ferroelectric/piezoelectric materials, reviewing their physical properties in close connection to their application in the field of clean energy. Among other compounds, we focus on the archetypal compound Pb(Zr,Ti)O3 (or PZT), which is well studied and thus preferred for its reliable performance in applications. Also, we pay special attention to the advanced ferroelectric relaxor compound (1−x)Pb(Mg1/3Nb2/3)O3−xPbTiO3 (or PMN-xPT) due to its superior performance. The inhomogeneous composition that many kinds of such materials exhibit at the so-called morphotropic phase boundary is reviewed in connection to possible advantages that it may bring when applications are considered. [ABSTRACT FROM AUTHOR]

The radiolabeled iron oxide nanoparticles constitute an attractive choice to be used as dual-modality contrast agents (DMCAs) in nuclear medical diagnosis, due to their ability to combine the benefits of two imaging modalities, for instance single photon emission computed tomography (SPECT) with magnetic resonance imaging (MRI). Before the use of any DMCA, the investigation of its plasma extra- and on/intra cellular distribution in peripheral human blood is of paramount importance. Here, we focus on the in vitro investigation of the distribution of 99mTc-DPD-Fe3O4 DMCA in donated peripheral human blood (the ligand 2-3-dicarboxypropane-1-1-diphosphonic-acid is denoted as DPD). Initially, we described the experimental methods we performed for the radiosynthesis of the 99mTc-DPD-Fe3O4, the preparation of whole blood and blood plasma samples, and their incubation conditions with 99mTc-DPD-Fe3O4. More importantly, we employed a gamma-camera apparatus for the direct imaging of the 99mTc-DPD-Fe3O4-loaded whole blood and blood plasma samples when subjected to specialized centrifugation protocols. The direct comparison of the gamma-camera data obtained at the exact same samples before and after their centrifugation enabled us to clearly identify the distribution of the 99mTc-DPD-Fe3O4 in the two components, plasma and cells, of peripheral human blood. [ABSTRACT FROM AUTHOR]

Radiolabelled superparamagnetic iron oxide nanoparticles (SPIONs) are a promising nanomaterial for the development of dual radiation/hyperthermia cancer therapy. To that purpose, flower-shaped SPIONs with an exceptional heating capability were synthesised and coated with citrate, dextran or (3-aminopropyl)triethoxysilane. Both non-coated and coated SPIONs were nontoxic to CT-26 mouse colon cancer cells up to 1.0 mg mlâˆ'1 in vitro. In an oscillating magnetic field, citrate-coated SPIONs (CA/SPIONs) displayed the highest heating rate (SAR  ∼ 253 W gâˆ'1) and the strongest hyperthermia effects against CT-26 cells. Labelling of the CA/SPIONs by the 90Y radionuclide, emitting βâˆ' radiation with an average/maximum energy of 0.94/2.23 MeV, and deep tissue penetration generated 90Y-CA/SPIONs intended for the therapy of solid tumours. However, intravenous injection of 90Y-CA/SPIONs in CT-26 xenograft-bearing mice resulted in low tumour accumulation. On the contrary, intratumoural injection resulted in long-term retention at the injection site. A single intratumoural injection of 0.25 mg CA/SPIONs followed by 30-min courses of magnetic hyperthermia for four consecutive days caused a moderate antitumour effect against CT-26 and 4T1 mouse tumour xenografts. Intratumoural application of 1.85 MBq/0.25 mg 90Y-CA/SPIONs, alone or combined with hyperthermia, caused a significant (P  ≤ 0.01) antitumour effect without signs of systemic toxicity. The results confirm the suitability of 90Y-CA/SPIONs for monotherapy or dual magnetic hyperthermia-radionuclide nanobrachytherapy (NBT) of solid tumours. [ABSTRACT FROM AUTHOR]

The combination of two imaging modalities in a single agent has received increasing attention during the last few years, since its synergistic action guarantees both accurate and timely diagnosis. For this reason, dual-modality contrast agents (DMCAs), such as radiolabeled iron oxide (namely Fe3O4) nanoparticles, constitute a powerful tool in diagnostic applications. In this respect, here we focus on the synthesis of a potential single photon emission computed tomography/magnetic resonance imaging (SPECT/MRI) DMCA, which consists of Fe3O4 nanoparticles, surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) and radiolabeled with 99mTc, [99mTc]Tc-DPD-Fe3O4. The in vitro stability results showed that this DMCA is highly stable after 24 h of incubation in phosphate buffer saline (~92.3% intact), while it is adequately stable after 24 h of incubation with human serum (~67.3% intact). Subsequently, [99mTc]Tc-DPD-Fe3O4 DMCA was evaluated in vivo in mice models through standard biodistribution studies, MR imaging and gamma-camera imaging. All techniques provided consistent results, clearly evidencing noticeable liver uptake. Our work documents that [99mTc]Tc-DPD-Fe3O4 has all the necessary characteristics to be a potential DMCA. [ABSTRACT FROM AUTHOR]

It has been proven and confirmed in numerous repeated tests, that the use of a combination of several therapeutic methods gives much better treatment results than in the case of separate therapies. Particularly promising is the combination of ionizing radiation and magnetic hyperthermia in one drug. To achieve this objective, magnetite nanoparticles have been modified in their core with α emitter 225 Ac, in an amount affecting only slightly their magnetic properties. By 3-phosphonopropionic acid (CEPA) linker nanoparticles were conjugated covalently with trastuzumab (Herceptin®), a monoclonal antibody that recognizes ovarian and breast cancer cells overexpressing the HER2 receptors. The synthesized bioconjugates were characterized by transmission electron microscopy (TEM), Dynamic Light Scattering (DLS) measurement, thermogravimetric analysis (TGA) and application of 131 I-labeled trastuzumab for quantification of the bound biomolecule. The obtained results show that one 225 Ac@Fe 3 O 4 -CEPA-trastuzumab bioconjugate contains an average of 8-11 molecules of trastuzumab. The labeled nanoparticles almost quantitatively retain 225 Ac (>98%) in phosphate-buffered saline (PBS) and physiological salt, and more than 90% of 221 Fr and 213 Bi over 10 days. In human serum after 10 days, the fraction of 225 Ac released from 225 Ac@Fe 3 O 4 was still less than 2%, but the retention of 221 Fr and 213 Bi decreased to 70%. The synthesized 225 Ac@Fe 3 O 4 -CEPA-trastuzumab bioconjugates have shown a high cytotoxic effect toward SKOV-3 ovarian cancer cells expressing HER2 receptor in-vitro. The in-vivo studies indicate that this bioconjugate exhibits properties suitable for the treatment of cancer cells by intratumoral or post-resection injection. The intravenous injection of the 225 Ac@Fe 3 O 4 -CEPA-trastuzumab radiobioconjugate is excluded due to its high accumulation in the liver, lungs and spleen. Additionally, the high value of a specific absorption rate (SAR) allows its use in a new very perspective combination of α radionuclide therapy with magnetic hyperthermia.